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Frame-based and frameless stereotactic radiosurgery 
for intracranial and extracranial tumors
Zbigniew Petrovich, Cheng Yu
P u r p o s e.  During the past 10 years stereotactic frame-based radiosurgery (SRS) emerged as an important treatment
modality in the management of selected intracranial lesions. More recently, frameless SRS has extended the potential of ibis
treatment to include lesions virtually in any site of the body.
Pa t i e n t s  a n d  m e t h o d s.  Many thousands of patients are being treated annually with frame-based SRS limited to the
cranial cavity. A total of 180,222 patients were treated to December 2001 with gamma knife (GK) and, very likely, a similar
number was treated with various linear accelerator based SRS systems. Frameless SRS has been performed uncommonly until
cyber knife (CK) became available. Over 3,000 patients were treated with CK in the US and Japan. This included patients
treated for extracranial lesions. Treatment results in patients treated with GK at University of Southern California (USC) will
be presented.
R e s u l t s.  From 1994 to 2002, a total of 1,126 patients received GK at USC for various indications. Since metastatic tumor
constituted the largest (42.4%) diagnostic category treated, the outcome in this group is specifically discussed. The overall
median survival was 9.2 months. The median survival was 8.3, 9.0, 17 and 12 months, for melanoma, lung cancer, breast
cancer and renal cell carcinoma, respectively. In multivariate analysis Karnofsky's performance status (70 vs. >70), status of
systemic disease (inactive vs. active), tumor histology and total intracranial tumor volume were the only important factors
predictive of survival, p=0.0001. Cause of death was found to be due to CNS problems in about 25% of patients with
a diagnosis other than melanoma, while it was 42% in those with melanoma. GK SRS was given on an outpatient basis and
was very well tolerated by the patients. Symptomatic focal radionecrosis requiring craniotomy for its removal was noted in <5%
of patients.
C o n c l u s i o n s.  An excellent palliative benefit was obtained in nearly all patients. The treatment was compatible with
a good quality of life.
Radioterapia stereotaktyczna, z unieruchomieniem lub bez, 
w leczeniu guzów Êród- i pozaczaszkowych
C e l.  W ciàgu ostatnich 10 lat radioterapia stereotaktyczna sta∏a si´ wiodàcà metodà terapii wybranych zmian
wewnàtrzczaszkowych. Ostatnio wskazania do radioterapii stereotaktycznej znacznie si´ poszerzy∏y, obejmujàc zmiany
praktycznie w dowolnej lokalizacji, co wià˝e si´ z mo˝liwoÊcià zrezygnowania ze stosowania unieruchomienia dzi´ki post´pom
technik wizualizacji.
M a t e r i a ∏  i  m e t o d y.  Co roku wiele tysi´cy chorych poddawanych jest leczeniu zmian wewnàtrzczaszkowych technikà
radioterapii stereotaktycznej. Do grudnia 2001 r. metod´ tak zwanego gamma-no˝a (Gamma-knife) zastosowano u 180 222
chorych i, prawdopodobnie, u porównywalnej grupy chorych wykorzystano ró˝ne inne systemy radioterapii stereotaktycznej,
z zastosowaniem akceleratorów liniowych. Radioterapia stereotaktyczna bez unieruchomienia stosowana by∏a rzadko,
dopóki nie wprowadzono do u˝ycia tzw. cyber-no˝a (Cyber-knife - CK). Na terenie Stanów Zjednoczonych i w Japonii
technik´ CK zastosowano dotychczas u oko∏o 3000 chorych, w tym równie˝ z guzami pozaczaszkowymi. W pracy
przedstawiono doÊwiadczenia University of Southern California  w zakresie leczenia chorych z zastosowaniem GK.
W y n i k i.  W latach 1994-2001 technik´ GK zastosowano, z ró˝nych wskazaƒ, u 1126 chorych. Najcz´Êciej leczono guzy
przerzutowe (42,4% chorych), a zatem ta grupa chorych zosta∏a najszerzej omówiona. Ca∏kowita mediana prze˝ycia wynios∏a
9,2 miesiàca - odpowiednio 8,3; 9,0; 17 i 12 miesi´cy dla chorych z czerniakiem, rakiem p∏uca, rakiem piersi i rakiem nerki.
Po zastosowaniu analizy wielowariantowej wykazano, ˝e jedynymi czynnikami istotnymi dla prze˝ycia by∏y: ocena stanu
ogólnego wg skali Karnofsky'ego (70 vs.>70), stadium choroby systemowej (nieaktywna vs. aktywna), typ histologiczny
Department of Radiation Oncology,
University of Southern California School of Medicine, 
Los Angeles, California, USA
509
Introduction
In the last two decades of the 20th century there bas been
an unprecedented growth of computer technology, which
propelled the development of progressively more
sophisticated, imaging techniques. This was particularly
true in the case of computerized axial tomography
(CT) and magnetic resonance imaging (MRI). In this
environment of technological innovations there has been
an increasing interest in stereotactic radiosurgery (SRS).
The wide use of SRS helped to redefine the management
of patients with virtually all benign and malignant brain
lesions and selected functional disorders [1]. SRS typically
uses various energy static or dynamic (multiple arcs)
photon beams and, less frequently, proton beams. The
main difference between the conventional external beam
radiotherapy and SRS is the ability of the latter to
precisely deliver a high dose of radiation to a well-defined
and relatively small target volume usually using a single
radiation fraction. There is a sharp radiation dose fall
off outside of the target volume thus optimizing
protection of the normal brain tissue.
In the late 1960's gamma knife (GK) SRS was
introduced to the clinic by a Swedish neurosurgeon Dr.
Lars Laksell. The current GK models use 201 fixed
Cobalt-60 beams. In the early 1980's, in Europe and later
in the US there was a development of linear accelerator-
based SRS systems. The present day systems most
frequently use 4-6 MV photon beams. Both GK and
accelerator based systems require a rigid immobilization
with the use of various design head frames. This requi-
rement makes the treatment somewhat uncomfortable
to the patient and multi-fraction SRS becomes imprac-
tical.
In the early 1990's a dedicated frameless SRS system,
called cyber knife (CK) was developed by a Stanford
University neurosurgeon Dr. John Adler [2-5]. CK uses
a specially designed and light weight 6 MV, linear
accelerator, which is attached to a robotic arm and it
contains a sophisticated imaging system allowing for a real
time verification of the targeting accuracy.
The development of CK was a major event in SRS
for the following reasons: 1. It made rigid head frames to
a large extent obsolete thus improving the treatment
tolerance; 2. It permitted for an easy use of multifraction
SRS; and 3. It most importantly extended the application
of SRS to any part of the human anatomy. It is apparent
that this new SRS system will find a very important place
in the management of patients with benign and malignant
primary and metastatic tumors. Wide application of CK is
likely to result in an improvement of the quality of life of
oncological patients. CK frameless system clearly
represents a new important dimension in the field of
radiosurgery and the very future of SRS.
Gamma Knife SRS
GK SRS is a commonly applied treatment for a wide
spectrum of intracranial lesions or functional disorders.
The interest in this treatment has been increasing over the
past decade. At the present time there are over 170 GK
facilities worldwide. A total of over 180,000 patients were
treated worldwide to December 31, 2001 (Table I). Most
(51%) patients were treated in Asia, with the US
contributing 28% to the total and Europe 20%. In the
early days of GK SRS functional disorders, vascular
lesions and benign tumors were primarily treated. At this
time malignant tumors represent 40.4% of all GK
treatments, with metastatic lesions being clearly the
guza oraz ca∏kowita Êródczaszkowa masa nowotworu (p=0,0001). Zmiany w oÊrodkowym uk∏adzie nerwowym by∏y przyczynà
zgonu u ok. 25% chorych z rozpoznaniem innym ni˝ czerniak i u ok. 42% chorych z czerniakiem. Radioterapia stereotaktyczna
z u˝yciem GK by∏a stosowana w trybie ambulatoryjnym i by∏a bardzo dobrze tolerowana przez chorych. Objawowa ogniskowo
wyst´pujàca martwica tkanek, spowodowana radioterapià, wymaga∏a interwencji neurochirurgicznej u mniej ni˝ 5% chorych.
W n i o s k i.  U niemal wszystkich chorych obserwowano znakomite wyniki leczenia paliatywnego. Post´powanie zapewnia∏o
dobrà jakoÊç ˝ycia.
Key words: Frame-based, frameless stereotactic radiosurgery
S∏owa kluczowe: radioterapia stereotaktyczna (z unieruchomieniem, bez unieruchomienia)
Table. I. Malignant and benign tumors treated with gamma knife
word-wide to December 31.2001*
Tumor N %
Malignant
Metastasis 53,011 72.9
Gliomas 14,778 20.3
Nasopharyngeal ca 828 1.1
Uveal melanoma 705 1.0
Glomus tumor 515 0.7
Hamangiopericytoma 511 0.7
Chondrosarcoma 190 0.3
Other malignant tumors 2,171 2.9
TOTAL 72,709 100.0
Benign
Meningioma 22,529 34.8
Acoustic neuroma 17,154 26.5
Pituitary adenoma 15,816 24.4
Craniopharyngioma 1,955 3.0
Pineal tumor 1,941 3.0
Trigeminal neuroma 1,118 1.7
Schwannoma 1,041 1.6
Chordoma 930 1.4
Hemangioblastoma 883 1.3
Other benign tumors 1,355 2.1
TOTAL 64,722 100.0
TOTAL all tumors 137,431 76.2
* Courtesy of Leksell Gamma Knife Society
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number one indication for this therapy (Table I). Among
benign tumors the most common indication for GK is
meningioma followed by acoustic neuroma and pituitary
adenoma. A particularly useful indication for GK SRS
is represented by tumors located in the cavernous sinus
where SRS obtained results have been excellent [6].
Similarly, treatment outcomes in patients with recurrent
or persistent pituitary adenomas following transsphe-
noidal resection have also been excellent [7-10]. An
important and growing indication for GK SRS is acoustic
neuroma where there is reported a high incidence of
tumor control rates and a good preservation of hearing.
Illustrations of treatment plans for various benign tumors
including chordoma, meningioma and pituitary adenoma,
obtained with model C, GK SRS at USC are shown in
Figure 1 through 4. All four tumors were successfully
treated with a good protection from therapeutic doses
of radiation of the adjacent important and radiosensitive
normal structures. The use of small (8 mm) collimators
and multiple isocenters facilitated development of good
conformal treatment plans, which were critically
important in meeting the above defined goals.
Vascular lesions (primarily arteriovenous malfor-
mations) remain an important indication for GK
representing over 17% of all patients treated with this
modality (Table II). In the group of functional disorders,
trigeminal neuralgia represents the most frequently used
and important indication for GK (Table II). Treatment
for epilepsy and Parkinson' s disease intractable to
medical therapy are relatively new indications for GK,
which are currently being investigated. A caution needs to
be exercised with the use of SRS for functional disorders,
since treatment outcomes in this group of diseases is
frequently not well defined and it is difficult to objectively
measure.
Figure 1b
Figure 1
1a. This is a case of a 16-year old female patient who was diagnosed
with a large clival chordoma. She underwent transsphenoidal surgery
with subtotal resection for a 2.3x2.4x2.4 cm tumor of the c1ivus displacing
the basilar arteries and involving the posterior part of the sphenoid
sinus. Residual tumor was noted together with microscopic evidence
of sphenoid sinus involvement. About 7 months following surgery
she presented for GK SRS. On MRI obtained for the GK treatment
planning a 2.7x2.3x2.7 cm mass was noted. The patient was treated to
16 Gy defined to the 50% isodose line with the use of 8 mm collimators
and 8 isocenters. Total tumor volume was 8,3 cm3 and total volume
treated was 13.4 cm3 with 100% of the tumor included in the 50% isodose
line. Excellent conformal treatment plan was obtained and it is
demonstrated on axial coronal and sagittal MRI views. A good treatment
tolerance was noted with no change in the tumor appearance and
dimensions during 1 year of observation.
1b. Dose volume histogram is provided for this patient.
Figure 1a
Table II. Vascular lesions and functional disorders treated 
with gamma knife world-wide to December 31,2001*
Vascular N %
AVM 28,925 93.7
Aneurysm 112 0.4
Other vascular 1,828 5.9
TOTAL 30,865 100.0
Functional Disorders
Trigeminal neuralgia 8,761 73.5
Epilepsy 1,320 11.1
Parkinson's disease 988 8.3
Intracable pain 346 2.9
Psychoneurosis 103 0.9
Other 408 3.4
TOTAL 11,926 100.0
TOTAL vascular& functional disorders 42,791 23.7
* Courtesy of Leksell Gamma Knife Society
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Figure 2b
Figure 2
2a. The patient is a 60-year old female diagnosed 6 years before with
a large left parasellar mass. She was treated with a craniotomy and total
gross tumor removal. Histological diagnosis was that of meningioma.
At this time patient presented with a right medial temporal lobe
meningioma measuring 2.5x3.5x1.6 cm. The patient was treated with
GK SRS receiving 16 Gy to the 50% isodose line with 5 isocenters.
Tumor vo1ume was 4.4 cm3 and the treated volume was 6.5 cm3 with
100% of the tumor encompassed by the 50% isodose line. Special care
was taken to protect the adjacent pons from high radiation dose.
2b. Dose volume histogram.
Figure 2a
Figure 3b
Figure 3
3a. This patient is a 67-year old female who presented with nausea,
vomiting and ataxia. She was diagnosed with peripontine meningioma.
Her tumor likely originated in petroclinoid area extending into the
Meckel's cave and the posterior part of the right cavernous sinus and an
obvious encroachment on the adjacent pons. The lesion measured
30x35x32 mm. GK SRS was felt to be the only available effective
treatment for this patient. She received 15 Gy to the 50% isodose line
using 11 isocenters with 8mm collimators. A good conformal treatment
plan was developed with 100% of the tumor being treated. Please note
the 50% isodose line being close to the tumor minimizing radiation
exposure to the pons.
3b. Dose volume histogram.
Figure 3a
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Linear Accelerator Based SRS Systems
It is believed that this form of SRS is as frequently applied
as GK. Radiation dosimetry in most cases is about
equivalent to that of GK. In recent years, dedicated SRS
systems have become widely available making this
treatment modality more attractive than in the past. The
main problem, however, is a difficulty in obtaining reliable
data from many hundreds of medical centers worldwide
which operate such linac-based SRS systems. The
reported treatment results have be en excellent and equal
to the best outcomes obtained with GK [11-14].
Frameless SRS
As it has already been stated, frameless stereotactic
systems are more appealing since they provide a better
alternative to the more invasive head frames. Patients
can be treated most of the time in greater comfort without
the need for local anesthesia or systemic sedation. The
use of more than one fraction treatment course is readily
available. There is also a major advantage in its ability
to treat intracranial as well as all extracranial targets.
Preliminary data on the experience with frameless
stereotactic radiotherapy was reported from University of
Florida at Gainesville, Florida [15]. Apparently, treatment
reproducibility was reported to be excellent with very
small translational and rotational errors.
The full stereotactic potential, however, was realized
with the introduction of CK [2-5]. This innovative
instrument utilizes a lightweight 6 MV linear accelerator
operated with a computer controlled robotic arm and
real time image verification of a treated target [3]. CK is
being phased in a growing number of medical centers in
the US and Japan.
This instrument was recently installed also at USC.
The increased availability of CK in turn helps to study
the treatment efficacy in various intracranial and
extracranial lesions, thus allows for a relatively rapid
expansion of the indications for stereotactic radiosurgery
[16-19]. Carefully selected spinal tumors and vascular
malformations are particularly appealing indications for
CK [17-19]. The procedure is performed on an outpatient
basis without the need for anesthesia or rigid, bone-
anchored fixation. The treatment accuracy has been
excellent with dose delivery within a mean of 1.5 mm of
the intended target [17]. Patient movement during the
treatment delivery was insignificant with a mean of 0.5
mm. Typically, a single, large radiation fraction is used
for the treatment with same patients being considered
for two or more fractions [17, 19]. CK boost dose to
augment external beam radiotherapy for carcinoma of
the nasopharynx bas been found to be effective in
reducing radiotherapy toxicity and increasing tumor
response rates as compared to those obtained with the
conventional radiotherapy alone [16]. Indications for CK
either well established or under study include the
following: 1. Selected intracranial benign and malignant
tumors; 2. Intracranial and spinal AVM; 3. Intracranial
Figure 4b
Figure 4
4a. A 19-year old male patient was originally diagnosed 26 months ago
with prolactin- secreting pituitary adenoma. The treatment consisted
with a transsphenoidal procedure with a steep fall in the serum prolactin
level. Prolactin level, however, began to increase and the patient was
diagnosed with a recurrent tumor in the left cavernous sinus. The tumor
measured 28x25x20 mm. In order to keep the radiation dose to the left
optic nerve to < 8 Gy a total of 16 Gy instead of the planned 18 Gy
was given using 9 isocenters with 8 mm collimators. A total tumor volume
was 5.2 cm3 with 100% of this volume being treated. Please note a very
good conformal treatment plan shown in axial, coronal and sagittal views.
There was no treatment related toxicity.
4b. Dose volume histogram.
Figure 4a
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functional disorders such as trigeminal neuralgia;
4. Selected benign and malignant spinal tumors;
5. Primary or recurrent tumors of the upper aero-digestive
passages; 6. Solitary primary or metastatic lung cancer;
7. Carcinoma of the pancreas; 8. Selected liver metastasis;
9. Adrenal metastasis; 10. Selected patients with renal
cell carcinoma; and 11. Adenocarcinoma of the prostate.
Many other indications for CK are currently being
considered for clinical studies.
USC Stereotactic Program
Over the past 25 years USC has developed a strong
interest in the SRS program (Table III). This was initiated
in 1980 with stereotactic brachytherapy using Ir-192.
Following the ana1ysis of treatment outcomes in this
group of patients, no significant improvement in survival
or quality of life was detected. There was also a relatively
high cost to this program as well as treatment toxicity.
Based on the above findings, the stereotactic brachy-
therapy program was phased out at USC in the late 1980s
[20]. A linear accelerator based SRS system was
developed at USC in 1985, initially for intracranial targets
and in 1995 it was expanded to include selected
extracranial sites. In 1994, our SRS program was further
augmented with a gamma knife model U, which in 2000
was replaced with model C. In 2002, we acquired a cyber
knife. Due to the availability of all basic stereotactic
instruments at USC, we have a true privilege of being
able to select an optimal treatment mode for a given
clinical problem [21]. During the past 20 years we
developed a well-functioning, multidisciplinary radio-
surgery team (Table IV). Based on our experience we
believe that the presence of such a team in a medical
center constitutes a basic requirement prior to considering
treatment of patients with SRS.
Materials and methods
A total of 1,126 patients were treated with GK at USC between
1994 and 2002. They received 1,411 separate treatment sessions
for the management of 2,132 lesions (Table V). Metastatic
lesions were treated in 42.4%, meningioma in 15.3% and
malignant glioma in 9.4% patients. Other diagnoses were less
commonly treated (Table V). Of the 477 patients presenting
with brain metastatic disease, there were the following primary
sites: cutaneous melanoma in 241 (50.5%), lung in 97 (20.3%)
and breast, RCC and tumors of other sites being next in
frequency (Table VI). Nearly 60% of patients presented with
a solitary metastasis, 25% had 2 lesions and 20% had 3 or more
lesions. None of the patients was treated for 6 or more
metastatic tumors. Median tumor volume was 0.9 cm3 with
a range from 0.1 to 40.3 cm3. All patients had histological
confirmation of a diagnosis of cancer at a primary site.
Histological confirmation of brain metastasis was available in
Table III. USC stereotactic program
Year began Treatment mode
1980 Streotactic brachytherapy  Ir-192
1985 Linac-based SRS - 4 MV photon beam
1994 Gamma Knife Model U-Co-60
1995 Linac-based Extracranial SRS-6-20 MV photon beams
2000 Gamma Knife Model C - Co-60
2002 Cyber Knife - 6 MV photon beam
Table V. Indications for gamma knife at USC
Diagnosis N Patients % N Treatments % Lesions %
Metastasis 477 42.4 716 50.7 1,370 64.3
Melanoma 241 50.5 368 51.4 752 54.9
Lung ca 97 20.3 150 20.9 280 20.4
Breast ca 41 8.6 67 9.4 115 8.4
Renal cell ca 32 6.7 48 6.7 78 5.7
Colon ca 16 3.3 21 2.9 37 2.7
Other sites 50 10.5 62 8.7 108 7.9
Meningioma 172 15.3 188 13.3 208 9.8
Malignant glioma 106 9.4 113 8.0 117 5.5
Pituitary adenoma 86 7.6 82 5.8 93 4.4
AVM 78 6.9 79 5.6 81 3.8
Trigeminal neuralgia 71 6.3 75 5.3 75 3.5
Acoustic neuroma 35 3.1 39 2.8 39 1.8
Other lesions 101 9.0 119 8.4 149 7.0
Total 1,126 100.0 1,411 100.0 2,132 100.0
Table IV. Radiosurgery Team
Radiosurgery Team
Neurosurgeon
Other surgical specialties:*
General surgery
Head & Neck surgery
Thoracic surgery
Urology
Radiation Oncologist
Radiation Physicist
Diagnostic Radiologist
Anesthesiologist
Pathologist
Technician
Nurse
* This applies to patients with extracranial sites
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patients who had a prior craniotomy or required a stereotactic
biopsy if a diagnosis of metastatic disease was questionable. An
overwhelming majority of the study patients, however, had their
diagnosis of brain metastasis based on MRI findings.
Most of the treated patients were referred from the outside
of this medical center and were presenting to us with already
completed diagnostic systemic work up. There was a slight (male
52% vs. female 48%) male preponderance. Patient age ranged
from 21 to 90 years with a median age of 57 years. Patients were
considered for GK SRS if they met the following criteria:
1. Stable general condition; 2. Expected survival >3 months; 3.
Solitary or < 6 lesions, in patients with prior whole brain
irradiation and recurrent tumor and up to 4 lesions in the
previously untreated patients; 4. The largest tumor diameter
was not to exceed 35 mm; 5. No acute signs and symptoms of
increased intracranial pressure. Patients with these signs were
considered for a conventional craniotomy. Important details on
patient work up and the treatment protocol have been presented
elsewhere [1, 9, 22-26]. A majority (57%) of patients presented
with active systemic disease while the remaining patients had
stable or inactive systemic disease. Prior to or subsequent to
GK SRS, whole brain irradiation (WBI) was given to 114 (24%)
patients. This treatment consisted of 30 Gy given in 2 weeks or
40 Gy in 4 weeks. Most of the treatment decisions regarding
WBI were made and the treatment itself was given in outside
medical centers. Nearly twice as many patients received WBI
prior to GK SRS while a minority received this treatment
following GK. Based on our review it was difficult to establish
a uniform pattern for indications for WBI. Same patients
received WBI for a single metastatic lesion while others had
a few to several lesions. All patients referred for GK following
WBI had evidence of intracranial tumor progression.
Radiation dose was determined based on a number of
parameters such as tumor volume, tumor histology and tumor
location in the brain. Basically, patients with a diagnosis of
melanoma, RCC or sarcoma were given a dose of 20-22 Gy
while patients with breast carcinoma or lung cancer were given
18-20 Gy. Median radiation dose for all patients was 20 Gy
usually defined to the 50% isodose line. Patients who were
treated following WBI received 16-18 Gy. Those patients with
tumors >9 cm3 received a 10% lower radiation dose than
expected from their histological diagnosis. Anti-seizure
medications were given prophylactically to patients with cortical
lesions usually for a period of 2 weeks following GK.
Dexamethason was given only to patients with symptoms and
signs of increased intracranial pressure or to those with larger
(>20 cm3) tumors. Survival was calculated in months from the
date of GK SRS. Informed consent was obtained in writing from
all patients. Patients had regular follow-up appointments usually
made on a quarterly basis. During each interaction interim
history was obtained and physical examination was performed. A
careful review of interim brain MRI studies and a comparison
with the pretreatment imaging was always performed. Median
follow-up was 9 months.
Treatment results
The 1- and 3-year actuarial survival was 33% and 10%,
respectively. The median survival for all patients was 9.2
months. It ranged tram a law of 5.8 months for lesions,
which included sarcoma and colon carcinoma, to a high of
17 months for those with breast cancer (Table VI). The
median survival for patients with melanoma was 8.3
months. The best median survival obtained in patients
with adenocarcinoma of the breast was likely related to
more effective chemotherapy available for this disease
resulting in a better control of extracranial tumor. A good
palliative benefit or stable quality of life in asymptomatic
patients was obtained in 80% of those treated. Patients
with lower (<70) score on the Karnofsky scale bad
a lower median survival when compared with those
presenting with higher (>70) scores, p=0.0001. The status
of systemic disease had an important influence on
survival. Patients with inactive or controlled systemic
disease had a median survival of 12 months as compared
to a median survival of 7 months for those with active
systemic disease, p=0.02. The number of metastatic
lesions in the brain did not have a significant influence on
survival while the total intracranial tumor volume was an
important predictor for survival, p=0.02. Local tumor
control in the treated site depended on the tumor volume
being >90% for patients with smaller (<3 cm3) lesions
and <80% for those with larger (>3 cm3) lesions. Tumor
response to GK SRS was a durable event with only few
patients manifesting a relapse in the treated site. About
25% of patients had a relapse elsewhere in the brain and
were considered for GK if they met the criteria
established for the patients treated de novo. The median
time to tumor recurrence outside of the GK treated
volume was 12 months. Treatment outcome in this group
of patients was as good as in those treated primarily.
Important details on salvage treatment outcome in the
patients who relapsed bas been presented elsewhere [23].
About 70% of the study patients are known to have
died. The pattern of failure in patients with melanoma
metastatic to the brain was distinctly different from those
with other histological diagnosis. In the 241 melanoma
patients the cause of death was due to a progressive
systemic disease, in 42% due to CNS causes and in 8%
the cause of death was not known. In the 236 patients
with the other histological diagnoses, systemic disease
was a cause of death in 70% while deaths due to CNS
causes was seen in 23%. The mode of death in patients
dying of CNS causes was a progressive disease outside
of GK treated volume including meningeal cranial or
spinal carcinomatosis. Very few (5%) patients died due to
cerebral hemorrhage.
Because of the well-known difficulty in accurate
measurements of intracranial tumor volume, we elected
to conduct a special study [27]. This study was limited to
122 consecutive patients with intracranial metastatic
melanoma treated with GK SRS between 1994 and 1999.
A special effort was made to measure pretreatment and
post treatment tumor volume accurately. This included
Table VI. Survival in patients with brain metastasis at USC
Primary site N % Median survival (months)
Melanoma 241 50.5 8.3
Lung 97 20.3 9.0
Breast 41 8.6 17.0
Kidney (RCC)* 32 6.7 12.0
Other 66 13.8 5.8
TOTAL 477 13.8 9.2
* Renal cell carcinoma
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patients with irregular tumor outline. Relevant MRI
images were scanned with the use of color film scanner
with a resolution 600 to 1200 dpi. Subsequently, tumor
images were reconstructed using GammaPlan software
(Electa Instruments).
Of the 122 study patients, 61 (50%) had solitary
tumors, 26 (21%) had 2 lesions, 18 (15%) had 3 lesions
and the remaining 17 (14%) had 4 or more lesions. A
median tumor volume was 0.8 cm3 and a mean volume
was 2.62 cm3. Median radiation dose was 20 Gy defined to
a median isodose line of 60%. The overall 1-year actuarial
survival was 26% with a median survival of 7 months.
The median survival from the time of diagnosis of brain
metastasis was 9.1 months and from the original diagnosis
of cutaneous melanoma, 47 months. A good correlation
was seen between survival and the total intracranial tumor
volume, p=0.0007. No such correlation existed between
the number of metastatic lesions and survival. In
multivariate analysis, total intracranial tumor vo1ume
and the status of systemic disease (active vs. inactive)
were the only significant factors predicting survival with
p=0.003 and 0.0065, respectively. Tumor location in-
fratentorial vs. supratentorial had borderline significance
(p=0.056) in predicting survival, and surprisingly, favored
patients presenting with infratentorial tumors. Per-
formance status, patient gender, number of intracranial
lesions, patient age and WBI were not significant factors
predicting survival.
Of the 122 patients, 86 (70%) are known to have
died. Death due to progressive systemic disease was noted
in 46%, due to CNS causes in 34% and the cause of death
was unknown in 20% of patients.
GK SRS was very tolerated by the study patients.
Symptomatic, focal necrosis requiring craniotomy was an
uncommon event seen in < 5% of patients.
Discussion
Stereotactic radiosurgery helped to redefine the
management of patients with many intracranial and in
recent years also extracranial tumors (5). This treatment,
which is being given on an outpatient basis, clearly
demonstrated in many studies excellent results in terms of
a high incidence of local tumor control, good quality
of life with a law incidence of toxicity and survival
comparable to that obtained with a conventional surgery
[1, 6, 8, 10, 11, 13, 22, 25, 27, 28-32]. It is apparent that
SRS should be offered to properly selected patients, as an
indiscriminate use of this modality may compromise
patient well-being or even decrease their survival. SRS has
become a treatment of choice in patients with smaller
acoustic neuromas, meningiomas as well as in those with
residual or recurrent pituitary adenomas particularly if
the tumor is invading the cavernous sinus [6-10].
Brain metastasis represents the most common CNS
tumor [33, 34]. In the US, over 200,000 patients are
diagnosed annually with this manifestation of metastatic
disease [11, 29, 33-39]. Extrapolating from these data and
assuming a similar incidence of metastasis in Poland, the
number of patients presenting annually in that country
should be well over 35,000. In the past, selected patients
with brain metastasis were treated with surgical excision
and/or WBI [34-40]. Median survival of patients treated
with WBI was <4 months [25, 26, 36-38]. Patients treated
with surgery had a longer median survival, but this was
very likely due to patient selection process rather than
a superiority of surgery over WBI [34, 35]. Patients
treated with WBI and surviving > 6 months had
a probability of development of late complications of
radiotherapy resulting in a sharp decrease of quality of
life. Additionally, WBI requires multiple visits for daily
treatments. During the past decade, patients with brain
metastasis became the most frequent indication for SRS.
The use of radiosurgery in this patient population resulted
in a substantial improvement in median survival over that
obtained with the use of WBI [11-14, 22, 24-32].
Treatment toxicity has been lower than that of WBI or
craniotomy. It is obvious, however, that radiosurgery is
a suitable treatment only for properly selected patients.
USC experience in the treatment of brain metastasis
is of interest. The unequivocal demonstration of the
importance of the total intracranial tumor volume on
survival and local tumor control bas major management
implications. We recommend a routine MRI screening
of high-risk patients for development of brain metastasis.
This is in order to diagnose metastatic disease in its early
stage with a law total intracranial tumor volume and prior
to the patient development of frequently distressing signs
and symptoms of CNS involvement. Early application of
SRS is expected to result in this patient population in an
improved survival and maintenance of good quality of
life.
Frameless SRS is clearly going to represent the
future of radiosurgery. In addition to similar indications
for treatment within the cranial cavity as those for GK or
linear accelerator based systems, CK will open all other
extracranial sites, which till now were to a large extent
unavailable for SRS. Solitary metastasis or small primary
lesions of the lungs represent an obvious indication for
frameless SRS. The same is true for selected patients
with liver or adrenal metastasis. It is expected that
some patients with residual or recurrent carcinoma of
gastrointestinal and genitourinary tract following surgical
resection will become a new and important indication
for CK SRS. Multiple phase I-II clinical trials are
currently under way in a number of medical centers.
These trials will help to better define the role of CK in the
management of patients with malignant and benign
tumors as well as same functional disorders.
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